Přehled o publikaci
2023
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Eva HOFERKOVÁ, G. CHIODIN et. al.Basic information
Original name
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
Authors
HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Eva HOFERKOVÁ, G. CHIODIN, Lenka KOŠŤÁLOVÁ, Gabriela MLADONICKÁ PAVLASOVÁ, Daniel FILIP, Pedro FARIA ZENI, Jan OPPELT, Anna PANOVSKÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, M. ŠIMKOVIČ, F. VRBACKÝ, Daniel LYSÁK, SM. FERNANDES, MS. DAVIDS, A. MAIQUES-DIAZ, S. CHARALAMPOPOULOU, I. MARTIN-SUBERO, JR. BROWN, Michael DOUBEK, Francesco FORCONI, Jiří MAYER and Marek MRÁZ
Edition
Czech Annual Cancer Research Meeting, Olomouc, 2023
Other information
Language
English
Type of outcome
Konferenční abstrakta
Country of publisher
Czech Republic
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Středoevropský technologický institut – Repository – Repository
Keywords in English
BCR inhibitors; CLL; PI3K-Akt activation
Links
LX22NPO5102, research and development project. MUNI/A/1224/2022, interní kód Repo. NV18-03-00054, research and development project. 802644, interní kód Repo.
Changed: 25/3/2024 03:21, RNDr. Daniel Jakubík
Abstract
V originále
Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.
